Printer Friendly
The Free Library
22,728,043 articles and books

Northfield Reaches Agreement With FDA on Special Protocol Assessment For Pivotal Phase III Trial; Establishes Basis for PolyHeme(R) Efficacy Claim.



Northfield Laboratories Northfield Laboratories Inc. (NASDAQ: NFLD) is the maker of PolyHeme, a hemoglobin-based oxygen carrier (HBOC). The company is based in Evanston, Illinois, with Dr. Steven A. Gould as its Chief Executive Officer. As of May 31, 2005, the company had 68 employees.  Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) on Special Protocol Assessment (SPA) for its pivotal Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA  prehospital trial with PolyHeme(R), the company's oxygen-carrying blood substitute.

"This is an exceptional achievement for Northfield. The SPA confirms that the data from our landmark trial will form the primary basis for an efficacy claim in a Biologics License Application for PolyHeme," said Steven A. Gould, M.D., Chairman and Chief Executive Officer. "SPA is not a routine event and this is not a routine trial. SPA is particularly useful for studies which assess novel, potentially life-saving therapies, especially when no approved drug In the United States, the FDA approves drugs. Before a drug can be prescribed, it must undergo an extensive FDA approval process. This process involves first testing the drug on animals or in medical labs.  is available to address a critical, unmet clinical need. Since agreement on SPA has only occurred in the Center for Biologics Evaluation and Research The Center for Biologics Evaluation and Research (CBER) is one of six main centers for the Food and Drug Administration, which is in the United States Department of Health and Human Services.  (CBER CB·er  
n.
One that uses a CB radio.
) on a limited number of occasions, this is a true milestone."

SPA represents acknowledgement and confirmation of a mutual agreement between a clinical trial sponsor and FDA that successful completion of the proposed trial will form the primary basis for an efficacy claim as part of product approval. SPA documents agreement on the design, primary efficacy endpoints, study conduct, data analysis, and the kind of labeling statements that could be made if the data are supportive and the product is approved. The agreement becomes part of the administrative record and may only be changed by mutual agreement of the parties, or if FDA identifies a substantial scientific issue relevant to safety or efficacy after the trial has begun.

"During the past year, we have been pursuing a regulatory strategy designed to reduce uncertainty and improve predictability by taking advantage of FDA regulations specifically intended to expedite the approval of novel therapies such as PolyHeme. SPA is the cornerstone of that strategy, and as we move towards licensure, this agreement provides the regulatory clarity that will facilitate our efforts to seek fast track designation for PolyHeme as a product intended to treat life-threatening blood loss when blood is unavailable," added Dr. Gould.

The PolyHeme trial is designed to assess the safety and efficacy of PolyHeme in improving survival when used to treat severely injured and bleeding trauma patients beginning at the scene of injury and continuing during ambulance transport to the hospital. Because the patients eligible for the study are unlikely to be able to provide consent due to the extent and nature of their injuries, the trial will be conducted under federal regulations that allow clinical research in emergency settings using an exception from the requirement for informed consent.

Northfield anticipates that approximately 20 Level I trauma centers throughout the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area.  will eventually participate in the PolyHeme trial, which has an expected enrollment of 720 patients. The process of public disclosure and community consultation required under the regulations is underway at a number of potential trial sites across the country. Patient enrollment will begin as soon as local IRBs complete their review process.

About Northfield

Northfield Laboratories is a leading developer of an oxygen-carrying blood substitute. Its product, PolyHeme(R), is the only blood substitute that has been rapidly and safely infused in sufficiently massive quantities in clinical trials to be considered useful in the treatment of large volume blood loss in trauma and surgical settings. PolyHeme(R) requires no cross matching cross matching or crossmatching
n.
1. A test for determining the compatibility between the blood of a donor and that of a recipient before transfusion; the clumping of red blood cells indicates incompatibility.

2.
, making it immediately available and compatible with all blood types, and has an extended shelf life of over 12 months.

Statements in this release that are not strictly historical are "forward-looking" statements that are made pursuant to the safe harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
 provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Forward-looking statements involve known and unknown risks, which may cause the company's actual results in the future to differ materially from expected results. These risks include, among others: competition from other blood substitute products; the possible refusal of the FDA to approve its request for fast track designation; the company's ability to obtain regulatory approval to market PolyHeme commercially; the availability of capital to finance the company's planned clinical trials and ongoing business operations Business operations are those activities involved in the running of a business for the purpose of producing value for the stakeholders. Compare business processes. The outcome of business operations is the harvesting of value from assets ; the company's and/or its representative's ability to successfully market and sell PolyHeme; the company's ability to manufacture PolyHeme in sufficient quantities; the company's ability to obtain an adequate supply of raw materials; the company's ability to maintain intellectual property protection for its proprietary product and to defend its existing intellectual property rights from challenges by third parties; and the extent to which the hospitals and physicians using PolyHeme are able to obtain third-party reimbursement, as described in the company's filings with the Securities and Exchange Commission.
   For further information contact:

   Steven A. Gould, M.D.                       Sharon L. Weinstein
   Chairman and Chief Executive Officer        Noonan Russo Presence
   (847) 864-3500                              (212) 845-4271
                                               sharon.weinstein@nrp-euro.com
   Sophia H. Twaddell
   Vice President, Corporate Communications
   (847) 864-3500
   stwaddell@northfieldlabs.com



CONTACT: Steven A. Gould, M.D., Chairman and Chief Executive Officer, +1-847-864-3500, or Sophia H. Twaddell, Vice President, Corporate Communications, +1-847-864-3500, stwaddell@northfieldlabs.com, both of Northfield Laboratories Inc.; or Sharon L. Weinstein of Noonan Russo Presence, +1-212-845-4271, sharon.weinstein@nrp-euro.com, for Northfield Laboratories Inc.
COPYRIGHT 2003 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Jun 12, 2003
Words:848
Previous Article:Comverge Announces Development of Nation's First Residential 'Virtual Peaking Capacity(TM)' Program; $40 Million Long-term Contract Signed with...
Next Article:Front Porch Digital Hires the Wilkin Group as Public and Investor Relations Firm.
Topics:



Related Articles
Northfield Laboratories Inc. Announces Result of Third Interim Analysis of PolyHeme Pivotal Phase III Study Data; - Study Continues Without...
Northfield Laboratories Inc. Reports First Quarter Financial Results.
Northfield Laboratories Announces Initiation of Public Disclosure Program For Phase III Prehospital Trial with PolyHeme(R).
Northfield Receives Clearance to Begin Prehospital Trauma Trial; Treatment to Begin With PolyHeme(R) at the Scene of Injury; - Company to Host...
Northfield Laboratories Submits Response To FDA.
Northfield Laboratories Proposes First Ambulance Blood Substitute Trial.
Northfield Laboratories Inc. Reports Fiscal 2004 Fourth Quarter and Year-End Financial Results.
Northfield Laboratories Inc. Announces Result of Second Interim Analysis of PolyHeme Pivotal Phase III Study Data.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters